Clinical Trial Update: Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating low-dose Rituximab combined with high-dose Dexamethasone as first-line therapy for Immune Thrombocytopenic Purpura has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenic Purpura

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Rituximab (rituximab)

Snippet

Sponsor: Hospital Universitario Dr. Jose E. Gonzalez | Conditions: Immune Thrombocytopenic Purpura | Phase 2 | Status: COMPLETED